Jeb Keiper is the chief executive officer and president of Nimbus Therapeutics, a biotechnology company harnessing quantum mechanics and computational approaches to structural biology to design breakthroughs in medicine. Jeb joined Nimbus in 2014 and oversees finance, business development, IP, legal, HR, PR, and operations at Nimbus. Since joining, Jeb has brought $775m into Nimbus via partnerships and financing, including Nimbus’ Series B financing in March 2015, their exclusive licensing agreement with Genentech in 2015, the sale of Nimbus’ clinical NASH program to Gilead in May 2016 for $400m upfront, the strategic immunology alliance with Celgene announced in October 2017, and a round of private expansion capital in 2018.
Prior to Nimbus, Jeb was vice president of business development at GSK Oncology and spent a decade at GSK in various BD leadership roles. Jeb led the oncology portion of the GSK-Novartis 3-business swap for $16b announced in April 2014.
Prior to GSK, Jeb was a consultant at McKinsey and worked in BD at TransForm Pharmaceuticals. Jeb began his career at Pfizer R&D as a bench chemist. He received four degrees from MIT; one in chemistry, two in chemical engineering, and an MBA from MIT Sloan.